Global Immortalized Cell Line Market Overview
The Immortalized Cell Line Market is expected to reach USD 2601.83 Million by 2030 at 4.90% CAGR during the forecast period 2022-2030  Immortalized cell lines are either tumorous cells that do not stop dividing or cells that have been artificially manipulated to proliferate indefinitely and can, thus, be cultured over several generations. These cell lines are expected to grow due to the rise in vaccine production and innovative technologies.
Besides, the ability of cell line culture to provide more physiologically relevant information and more accurate data in-vitro tests has led cell line culture systems to become acceptable in comparison to media culture.
The increasing application in biotech and pharmaceutical companies and hospitals, a growing number of patients in need of organ transplantation, and the rise in the patient population affected by cancer are the major drivers propelling market growth. However, the high cost of equipment and developing a stable strain of cell line and maintaining and preventing it from contamination may hinder the growth of the market.
Immortalized Cell Line Market Trends
The increasing demand for organ donation due to scarcity in the availability of organs is driving the need for artificially created biological cells. For instance, according to the US Department of Health & Human Services Organ Procurement and Transplantation Network (OPTN), as of November 2016, 121,678 patients were waiting for a life-saving organ transplant. This rising demand for an organ transplant is expected to drive the growth of the market during the forecast period. Additionally, increasing application in biotech and pharmaceutical companies and hospitals and rise in the patient population affected by cancer are likely to support market growth. On the other hand, the high cost of equipment and developing a stable strain of cell line and maintaining and preventing it from contamination is anticipated to hamper the market growth.
Immortalized Cell Line Market Size, by End User, 2017 (USD Million) Â 
Source: MRFR Analysis
Immortalized Cell Line Market Segment Insights
The immortalized cell line market has been segmented into method, application, and end user.Â
Based on the method, the global market has been segmented into virus induction, hTERT expression, inactivation of tumor suppression genes, and others. The virus induction segment is further divided into EBV genes, SV40 T antigen, HPV-16 E6/6 gene, and others. The hTERT expression segment is sub-segmented into P53 and Myc T58A.
The immortalized cell line market, based on application, is segmented into diagnostics,Â
drug discovery, vaccine production,Â
tissue engineering and regenerative medicine, and others.
Based on end user, the global market is segmented into pharmaceutical and biopharmaceutical companies, Contract Research Organizations (CROs), and research laboratories. The pharmaceutical and biopharmaceutical companies segment accounted for a market value of USD 1,323.79 million in 2017. Â
Â
Immortalized Cell Line Market Key Players
The prominent players in the immortalized cell line market areÂ
- Thermo Fisher Scientific (US)
- ATCC (American Type Culture Collection Inc.) (US)
- Valneva (France),Â
-
Sartorius AG (Germany)
- Lonza Group, AG (Switzerland)
- Merck KGaA (Germany)
- Selexis SA (Switzerland)
-
WuXi App Tec (China)
- European Collection of Authenticated Cell Cultures (ECACC) (Europe)
- Corning Incorporated (US)
Some of the key strategies followed by the players operating in the immortalized cell line market are innovation, product development, acquisition, and expansion.
Immortalized Clinell Line Market Share, by Region, 2017 (%)
 Source: MRFR Analysis
Immortalized Clinell Line Market Regional Insights
The immortalized cell e market, based on region, is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is estimated to dominate the immortalized cell line market during the forecast period. This is attributed to an increase in the occurrence of cancer, the presence of well-established pharmaceutical and biotechnology industry, increasing awareness of immortalized cell lines, and strong research funding.
The European market for immortalized cell line is expected to be the second-largest during the forecast period. Increasing government support, well-developed technology, and rising cases of cancer are expected to boost the growth of the market in this region. Â Â Â
Asia-Pacific is estimated to be the fastest-growing market due to the increasing expenditure on healthcare by government and private sector companies. Moreover, the growing awareness about healthcare and large untapped patient population have led to the increased focus of key players on expansion in this region. Furthermore, the region accounted for a market share of 17.8% in 2017.
The immortalized cell line market in the Middle East & Africa is expected to hold the least market share.
Immortalized Cell Line Industry Developments
In January 2024,Thermo Fisher Scientific Launched new Gibco™ Advanced DMEM/F12 media optimized for immortalized cell lines, claiming improved growth and performance.
In September2023,Lonza Group AG Announced partnership with CStone Pharmaceuticals to optimize and manufacture immortalized cell lines for CAR-T cell therapy development.
Immortalized Cell Line Market Segmentation
Immortalized Cell Line Method Outlook
- Virus Induction
- EBV genes
- SV40 T antigen
- HPV-16 E6/6 gene
- OthersÂ
- HTERT Expression
- P53
- Myc T58A
- Inactivation of Tumour Suppression Genes
- Others
Immortalized Cell Line Application Outlook
- Diagnostics
- Drug Discovery
- Vaccine Production
- Tissue Engineering and Regenerative Medicines
- Others
Immortalized Cell Line End User Outlook
- Pharmaceutical and Biopharmaceutical Companies
- Contract Research Organizations
- Research Laboratories
Immortalized Cell Line Regional Outlook
-
Americas
-
North America
-
South America
-
Europe
-
Western Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Rest of Western Europe
-
Eastern Europe
-
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Rest of Asia-Pacific
-
Research and development (R&D) companies
-
Government research institutes
-
Academic institutes and universities
Immortalized Cell Line Market Highlights:
